AIM Immunotech Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AIM Immunotech Inc. on October 17, 2019, reporting events that occurred on October 16, 2019. The Company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol "AIM".
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation adjustments.
- Ellen Lintal (CFO): Annual compensation increased by $50,000 to a total of $235,304 (includes base salary, medical/life insurance, and auto allowance).
- Peter W. Rodino, III: Annual compensation increased by $25,000.
Material Changes
The primary material change reported is the appointment of Peter W. Rodino, III as Chief Operating Officer (COO) effective October 16, 2019. Mr. Rodino retains his existing roles as General Counsel and Secretary. Additionally, the Board approved salary increases for Mr. Rodino and Ms. Lintal.
Management Commentary and Risks
Management highlighted Mr. Rodino's extensive background, including experience as Chairman and CEO of Crossroads Health Plan, an investment executive, and a trustee in Chapter 11 reorganizations. The filing does not disclose specific risks, contingencies, or unusual items beyond the standard executive changes.
Key Facts for Investor Verification
- Verify the impact of the new COO appointment on the Company's operational strategy.
- Confirm the total annual compensation figures for the CFO and COO against the Company's most recent Form 10-K.
- Review the Company's cash position to ensure it can sustain the increased executive compensation costs.